BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 24270167)

  • 1. Antifungal prophylaxis associated with decreased induction mortality rates and resources utilized in children with new-onset acute myeloid leukemia.
    Fisher BT; Kavcic M; Li Y; Seif AE; Bagatell R; Huang YS; Zaoutis T; Torp K; Leckerman KH; Aplenc R
    Clin Infect Dis; 2014 Feb; 58(4):502-8. PubMed ID: 24270167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011.
    Gomes MZ; Mulanovich VE; Jiang Y; Lewis RE; Kontoyiannis DP
    Antimicrob Agents Chemother; 2014; 58(2):865-73. PubMed ID: 24277033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy.
    Heng SC; Slavin MA; Al-Badriyeh D; Kirsa S; Seymour JF; Grigg A; Thursky K; Bajel A; Nation RL; Kong DC
    J Antimicrob Chemother; 2013 Jul; 68(7):1669-78. PubMed ID: 23485723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort.
    Vehreschild JJ; Rüping MJ; Wisplinghoff H; Farowski F; Steinbach A; Sims R; Stollorz A; Kreuzer KA; Hallek M; Bangard C; Cornely OA
    J Antimicrob Chemother; 2010 Jul; 65(7):1466-71. PubMed ID: 20410061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azole-based chemoprophylaxis of invasive fungal infections in paediatric patients with acute leukaemia: an internal audit.
    Yunus S; Pieper S; Kolve H; Goletz G; Jürgens H; Groll AH
    J Antimicrob Chemother; 2014 Mar; 69(3):815-20. PubMed ID: 24198097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes.
    Dahlén T; Kalin M; Cederlund K; Nordlander A; Björkholm M; Ljungman P; Blennow O
    Eur J Haematol; 2016 Feb; 96(2):175-80. PubMed ID: 25880378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy.
    Park H; Youk J; Shin DY; Hong J; Kim I; Kim NJ; Lee JO; Bang SM; Yoon SS; Park WB; Koh Y
    BMC Cancer; 2019 Apr; 19(1):358. PubMed ID: 30991992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effectiveness of itraconazole as antifungal prophylaxis in AML patients undergoing intensive chemotherapy in the modern era.
    Keighley CL; Manii P; Larsen SR; van Hal S
    Eur J Clin Microbiol Infect Dis; 2017 Feb; 36(2):213-217. PubMed ID: 27830376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment cost development of patients undergoing remission induction chemotherapy: a pharmacoeconomic analysis before and after introduction of posaconazole prophylaxis.
    Heimann SM; Cornely OA; Vehreschild MJ; Glossmann J; Kochanek M; Kreuzer KA; Hallek M; Vehreschild JJ
    Mycoses; 2014 Feb; 57(2):90-7. PubMed ID: 23790060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia.
    Al-Badriyeh D; Slavin M; Liew D; Thursky K; Downey M; Grigg A; Bajel A; Stewart K; Kong DC
    J Antimicrob Chemother; 2010 May; 65(5):1052-61. PubMed ID: 20237074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study.
    Mandhaniya S; Swaroop C; Thulkar S; Vishnubhatla S; Kabra SK; Xess I; Bakhshi S
    J Pediatr Hematol Oncol; 2011 Dec; 33(8):e333-41. PubMed ID: 22042283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of hospital construction with the development of healthcare associated environmental mold infections (HAEMI) in pediatric patients with leukemia.
    Pokala HR; Leonard D; Cox J; Metcalf P; McClay J; Siegel J; Winick N
    Pediatr Blood Cancer; 2014 Feb; 61(2):276-80. PubMed ID: 23970381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy.
    Busca A; Lessi F; Verga L; Candoni A; Cattaneo C; Cesaro S; Dragonetti G; Delia M; De Luca A; Guglielmi G; Tumbarello M; Martino G; Nadali G; Fanci R; Picardi M; Potenza L; Nosari A; Aversa F; Pagano L;
    Leuk Lymphoma; 2017 Dec; 58(12):2859-2864. PubMed ID: 28508692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children's Oncology Group.
    Sung L; Aplenc R; Alonzo TA; Gerbing RB; Lehrnbecher T; Gamis AS
    Blood; 2013 May; 121(18):3573-7. PubMed ID: 23471307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
    Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
    Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Infection-Related Mortality in Pediatric Acute Myeloid Leukemia without Preventive Antibiotics and Antifungals: Retrospective Cohort Study of a Single Center from a Middle-Income Country.
    Zengin E; Sarper N; Aylan Gelen S; Demirsoy U; Karadoğan M; Çakı Kılıç S; Öncel S; Arısoy ES; Dündar D
    Turk J Haematol; 2017 Dec; 34(4):340-344. PubMed ID: 28351828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.
    Cho SY; Lee DG; Choi JK; Lee HJ; Kim SH; Park SH; Choi SM; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS; Back H; Kang S; Lee EK
    Clin Ther; 2015 Sep; 37(9):2019-27. PubMed ID: 26188835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
    Busca A; Candoni A; Audisio E; Passera R; Bruno B; Monaco F; Mordini N; Vacca A; Delia M; Aversa F; Pagano L
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2214-2219. PubMed ID: 27667012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Incidences of Invasive Fungal Infections in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy without Systemic Antifungal Prophylaxis: A Prospective Observational Study in Taiwan.
    Tang JL; Kung HC; Lei WC; Yao M; Wu UI; Hsu SC; Lin CT; Li CC; Wu SJ; Hou HA; Chou WC; Huang SY; Tsay W; Chen YC; Chen YC; Chang SC; Ko BS; Tien HF
    PLoS One; 2015; 10(6):e0128410. PubMed ID: 26061179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe infections in children with acute leukemia undergoing intensive chemotherapy can successfully be prevented by ciprofloxacin, voriconazole, or micafungin prophylaxis.
    Yeh TC; Liu HC; Hou JY; Chen KH; Huang TH; Chang CY; Liang DC
    Cancer; 2014 Apr; 120(8):1255-62. PubMed ID: 24415457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.